Linaclotide New Drug Application (NDA) submitted to FDA.


Please see Important Risk Information below.

LINZESS® (linaclotide) approved by FDA.

Hired approximately 160 Clinical Sales Specialists, continuing our transition to a commercial biotech.

Entered into a collaboration agreement with AstraZeneca AB to co-develop and co-commercialize linaclotide in China, Hong Kong and Macau.

CONSTELLA® (linaclotide) approved in Europe.

LINZESS® launched and made available to patients in the United States.


Gathered for our first Goalsapalooza, a now-annual tradition of celebrating progress toward corporate goals and our mission of empowering our team to deliver medicines to patients and value to shareholders.

Hosted our first Investor Day in New York City to showcase our progress developing innovative medicines for patients and building on our success with linaclotide to establish Ironwood as a leading therapeutics company.


More than 1 million total prescriptions written for LINZESS®, according to Quintiles IMS.


Top-line data reported from the Phase I study of IW-1973, our lead investigational soluble guanylate cyclase (sGC) stimulator.


Entered into a license agreement with AstraZeneca plc for the exclusive U.S. rights to all products containing lesinurad, establishing a new franchise for Ironwood.

Please see Important Risk Information below.

ZURAMPIC® (lesinurad) launched in the U.S.

Ironwood, Allergan, and the American College of Gastroenterology (ACG) launched Picture My IBS, an art competition aimed at helping IBS patients share their journey with the disease through art, with a goal of improving communication between patients and their doctors and, ultimately, patient care.

Celebrated the holiday season with a new take on our annual holiday party centered on giving back. Our collective effort supported thousands suffering from hunger and provided holiday cheer to local families in need.

LINZESS® approved in Japan.

Top-line Phase IIb data reported for linaclotide delayed release (DR).


Another dose of LINZESS® — 72mcg — approved in the U.S.

Expanded license agreement with Allergan (formerly Almirall) to partner on the potential development, manufacture and commercialization of linaclotide worldwide in all countries not previously covered by the agreement (other than China, Hong Kong, Macau, Japan and North America).

In partnership with patient advocacy group CreakyJoints, we conducted a survey of 1,000 gout patients and 500 caregivers and released compelling findings about misperceptions of the condition and its impact on daily life.

Positive top-line data reported from a Phase IIb trial of our product candidate being evaluated for persistent gastroesophageal reflux disease (GERD) — a condition affecting an estimated 10 million Americans.

Please see Important Risk Information below.

DUZALLO® (lesinurad and allopurinol) approved by the FDA.

In honor of the 5-year approval-versary of LINZESS®, a LINZESS® conference room was christened as part of our Great Drug Making program. The newly transformed room was unveiled at a ribbon cutting event.

Ironwood ranked sixth overall on Selling Power Magazine’s 2017 Best Companies to Sell For list.

DUZALLO® launched in the U.S.

Announced continued expansion of our sGC pipeline with mid-stage clinical trials evaluating our sGC stimulators in diabetic nephropathy, heart failure with preserved ejection fraction (HFpEF), achalasia, and sickle cell disease.


Ironwood celebrates 20th anniversary!